Lipid peroxidation occurs as a consequence of metabolism and plays a significant role in cellular dysfunction with aging. Free radicals strip electrons from membrane lipids in a cascading fashion, generating lipid peroxides and other harmful byproducts which damage DNA and proteins. Membrane integrity and fluidity are disrupted, resulting in impaired membrane transport and intracellular signaling, as well as damaging mitochondria, leading to the production of more free radicals.

Studies have found that this cascade can be inhibited, however, by replacing reactive hydrogens in candidate fatty acids with deuterium atoms, generating deuterated polyunsaturated fatty acids (D-PUFAs). This isotopic reinforcement makes D-PUFAs resistant to reactive oxygen species (ROS)-initiated chain reactions, allowing them to withstand oxidative damage. Furthermore, it has been demonstrated that the presence of even a small fraction of D-PUFAs among natural PUFAs in membranes will effectively inhibit lipid peroxidation, alleviating disease phenotypes in several disease models. Several clinical trials utilizing D-PUFAs have been conducted in humans for a diverse range of pathologies, particularly for cognition and memory, and safety is well-established.

Further, D-PUFAs can be provided in animal chow, eliminating unnecessary injections and associated stress on the animals. When consumed, D-PUFAs incorporate into membranes in many tissues, without any reports of toxicity.

Serum albumin is the most abundant circulating protein in mammalian plasma, accounting for approximately 60% of total blood protein. It has a critical role in maintaining the blood’s osmotic pressure and additionally serves as an important carrier protein for endogenous and exogenous ligands such as fatty acids, metal ions and drugs. It is, however, the third main function of serum albumin we are primarily interested in – that is, its role in the maintenance of intravascular redox homeostasis, a property dependent on the redox state of a free thiol on Cys34. Due to serum albumin’s abundance in plasma, this thiol contributes a large amount of ROS scavenging activity when in its reduced state, and changes in the percentage of reduced vs oxidized serum albumin are indicative in states of liver disease, renal dysfunction, and diabetes mellitus, as well as in aging.

There is promising evidence that repeated administration of physiochemically virgin serum albumin in saline can improve multiple healthspan metrics in aging mice, influencing both mean and maximum lifespan. In addition to bolstering redox buffering capacity, treatment in this way may also confer a plasma-diluting effect, which is known to rejuvenate multiple organs and tissues on its own.

The progressive loss of stem cell regenerative potential remains one of the most obvious consequences of aging and is a primary focus of rejuvenation therapeutics. Thus, therapies to restore stem cell functionality, including stem cell transplant, are promising strategies for longevity medicine. Stem cell aging remains a high-value target for rejuvenation therapeutics, particularly those aiming for a systemic benefit with possible lifespan extension. Therapeutic administration of stem cells is already demonstrated to improve disease and aging phenotypes in animals and in humans and is the focus of ongoing clinical trials.

Although it is believed that the vast majority of systemically administered stem cells are eliminated from the system within a few days of injection, there are still significant and much longer-lasting physiological changes which result from the body’s response to cell injections. It seems likely that the benefits of MSC therapy are via the ability of administered cells to induce changes in resident cells, promoting the switch to a regenerative phenotype, which further rejuvenates cells and tissues downstream.

Our first RMR study (RMR1) also included youthful stem cells as an intervention, however with some key differences, mainly in that it utilized lineage-depleted bone marrow stem cells (HSCs) isolated from young mice. While HSCs populate the cells of the blood and immune system, MSCs constitute an important part of the BM microenvironment that houses HSCs. In addition, the MSC lineage gives rise to many tissues including bone, fat, muscle, and cartilage, as well as endodermal and ectodermal tissues such as neurons, blood vessels, skin, and cells of the liver, pancreas, heart. MSCs can be derived from a variety of sources and can be reliably expanded ex vivo, permitting their use at scale and under repeat-dosing conditions.

Partial reprogramming involves the temporary activation of a set of genes known as the Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc), which can induce a state of cellular rejuvenation without altering the cell's original identity. This approach addresses the aging process at the cellular level, potentially complementing other interventions and providing a comprehensive strategy for age-related therapies.

The Yamanaka factors work by rewiring the cellular epigenome, erasing certain age-associated epigenetic marks and activating genes associated with youthful characteristics. This leads to functional rejuvenation in various tissues such as the kidney, skin, liver, and muscle, enhancing tissue health and restoring the regenerative capacity of aged cells, potentially slowing down age-related decline. Further, by reducing the expression of genes involved in inflammation, senescence, and stress response pathways, partial reprogramming may delay the onset and progression of age-related diseases which contribute significantly to mortality and reduced quality of life in aging individuals.

Partial reprogramming has thus attracted substantial interest in recent years both from a research and investment standpoint. Achieving efficient and safe delivery of reprogramming factors to specific cells or tissues in vivo, however, still presents a considerable challenge and the development of practical, targeted, and cost-effective delivery methods is vital for successful application. The delivery of these factors has historically been achieved using viral vectors or genetic modifications, however recent innovations have focused on liposome-mediated delivery as mRNA, and even chemical induction of reprogramming factors using reagents and small molecules.

The pro-inflammatory cytokine IL-11 has emerged as a promising longevity target due to its central role in age-related fibrosis and inflammation across multiple tissues. IL-11 production is upregulated in response to oxidative stress as a compensatory mechanism, yet sustained IL-11 activity paradoxically worsens tissue damage by promoting reactive oxygen species (ROS) production. This accumulation of ROS promotes cellular senescence, a condition where cells lose the ability to divide and repair tissue effectively.

In mice, inhibition of IL-11 signaling has recently demonstrated remarkable therapeutic effects in key organs that typically deteriorate with age. In the heart, IL-11 inhibition prevents and reverses cardiac fibrosis by blocking myofibroblast activation and reducing extracellular matrix deposition, ultimately preserving cardiac function. Similarly, in the liver, disrupting IL-11 signaling reduces hepatic stellate cell activation and fibrosis, while improving metabolic parameters and glucose homeostasis. These effects, and similar results in adipose tissue and skeletal muscle, appear to be mediated through the interruption of ERK/MAPK and STAT3 signaling pathways, which are key drivers of cellular senescence and tissue dysfunction.

The therapeutic potential extends beyond individual organs: inhibiting IL-11 shows systemic benefits by counteracting its effects on stromal cells and the broader inflammatory environment. For example, increased IL-11 with age dysregulates immune responses by stimulating persistent inflammation, which causes immune cells to infiltrate tissues and leads to a pro-fibrotic state rather than resolution. Mice lacking IL-11 signaling show improved health outcomes across multiple organ systems, while preliminary research in aged animal models indicates that IL-11 inhibition not only improves tissue-specific functions but may also contribute to lifespan extension.

Human studies have revealed increased IL-11 expression in various age-related pathologies, including heart failure, liver cirrhosis, and chronic inflammatory conditions, suggesting strong translational relevance. The broad tissue distribution of IL-11 and its signaling components, combined with its role in fundamental aging processes like fibrosis and inflammation, positions IL-11 inhibition as a potentially powerful intervention for extending healthspan.

Overactivity of Cdc42, a small RhoGTPase, plays a significant role in the aging process by disrupting cellular functions essential for maintaining tissue homeostasis. Cdc42 activity increases with age in various cell types - including hematopoietic stem cells (HSCs), mesenchymal stem cells, and intestinal epithelial cells - thereby contributing to functional declines in cell populations critical for regeneration and repair. For instance, in HSCs, increased Cdc42 levels lead to decreased regenerative capacity and cellular exhaustion, which weakens the immune system’s ability to respond to pathogens and is a core contributor to immunosenescence in older adults.

Factors including oxidative stress, altered lipid composition in cell membranes, and shifts in the cytokine milieu - parts of a chronic inflammatory state dubbed "inflammaging" - all contribute to amplifying Cdc42 activity with age. The pathophysiological implications of Cdc42 elevation extend across various systems. In tissues dependent on precise cellular architecture, like neural and epithelial systems, Cdc42-induced disruptions in cell polarity can lead to structural disorganization and functional decline. More broadly, its effects can disrupt insulin and leptin signaling, exacerbating age-related metabolic disorders such as obesity and type 2 diabetes. These findings underscore Cdc42 as a key player in degenerative diseases linked to aging, making it a prime therapeutic target for age-related pathologies.

CASIN, a small molecule Cdc42 inhibitor, has shown promise in preclinical studies by restoring functionality in aged HSCs, enhancing their regenerative capacity, and decreasing systemic inflammation. Such inhibition not only reduces senescence markers but also addresses inflammaging at its cellular root, offering a strategy to potentially extend healthy lifespan by preserving tissue and immune function and slowing age-related degenerative processes. CASIN and other Cdc42 inhibitors thus highlight a promising approach to rejuvenating stem cell populations and addressing aging’s systemic impacts at the molecular level.

The potential senolytic mechanism of long chain fatty acid-CoA synthetase (LC-FACS) inhibition is rooted in the distinct metabolic vulnerabilities of senescent cells. These cells demonstrate markedly elevated levels of lysophosphatidylcholine (lysoPC) and free arachidonic acid, similar to the lipid profile seen in ferroptotic cells - those undergoing regulated iron-mediated cell death - a connection particularly relevant given recent evidence that senescent cells show increased sensitivity to ferroptosis inducers.

The accumulation of these bioactive lipids suggests compromised membrane homeostasis, which has been demonstrated to correlate with increased sensitivity to additional membrane stress in multiple models of cellular senescence. By inhibiting LC-FACS we aim to impair the activation of free fatty acids to their CoA derivatives, blocking their incorporation into phospholipids and their entry into beta-oxidative metabolism. This should be particularly devastating for senescent cells, which already show impaired lipid homeostasis and increased membrane permeability. The mechanism is analogous to the demonstrated senolytic activity of dasatinib, which disrupts membrane integrity, but potentially more selective due to the pre-existing lipid abnormalities in senescent cells.

Supporting this approach, recent studies have shown that senescent cells exhibit reduced expression of membrane repair proteins and decreased capacity to handle acute membrane stress. The combinatorial effect of existing lysoPC-mediated membrane disruption, elevated free AA levels, and a blockade of LC-FACS would likely exceed the survival threshold specifically in senescent cells, while healthy cells could maintain viability through intact compensatory mechanisms and better baseline membrane stability.

Therapeutic use of the "bonding hormone" oxytocin has emerged as a promising intervention for extending lifespan and promoting rejuvenation in various animal models, with studies consistently highlighting its capacity to reverse age-related decline and restore function across multiple systems through an array of rejuvenation mechanisms.

Oxytocin improves homeostatic regulation and reduces inflammation, key factors in improving metabolic health and resilience; enhances the regenerative capacity of aged muscle by activating muscle satellite cells, accelerating healing and staving off atrophy; promotes liver regeneration by increasing hepatocyte proliferation; preserves bone density and strength by stimulating osteoblast activity and reducing bone resorption; and increases neurogenesis and synaptic plasticity while reducing neuroinflammation, via the BDNF axis.

Collectively, these benefits may delay or prevent a similarly broad array of age-related conditions - potentially including the metabolic syndrome, sarcopenia, fibrosis of the heart and liver, osteoporosis, and neurodegenerative disease.

Molecular mechanisms underpinning oxytocin’s rejuvenative effects include activation of MAPK/ERK and STAT3 signaling pathways, reduction of oxidative stress, and modulation of inflammatory cytokines. Typical therapeutic regimens involve subcutaneous or intraperitoneal administration at doses of 0.5–2 mg/kg/day over periods ranging from days to weeks, depending on the target system.